

Closing share Price (27/04/2022)

**EUR 75.00**

Target valuation range

**EUR 79.00 - 96.00**

Risk	Low
Reuters	LUX.LU
Bloomberg	LXMP LX
Shares number (m)	20.10
Market cap. (m)	1,507
NAV 27/04/2022	102.66
(Discount)/Premium	-26.9%
1 year price perf.	24.0%
Diff. with Euro Stoxx	29.4%
Volume (sh./day)	1,358
H/L 1 year	79.50 - 54.50
Free Float	24.1%
Foyer Finance	50.4%
Sofina Group	6.1%
Stable Shareholders	16.6%
Treasury Shares	2.8%

### Company description

Luxempart is a Luxembourg based investment holding company with more than 25 years of existence. Luxempart invests in several European countries, mainly in the DACH region, Luxembourg, Belgium, France and Northern-Italy.



### Analyst:

**Joren Van Aken**

Equity Analyst

+32 2 662 88 83

j.vanaken@degroofpetercam.com

## Luxempart

### 2021: a year of transformation

This report is considered as a marketing communication. It has been commissioned and paid for by Luxempart and has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and is also not subject to any prohibition on dealing ahead of the dissemination of investment research.

With the annual report published, we circle back to the excellent results of Luxempart in 2021.

#### A year of investing

Investments in the direct investments portfolio amounted to EUR 206m, of which a sizeable stake of EUR 87m in Evariste (see our previous report on this acquisition [here](#)). The Group also added to its stake in SNP and Technotrans. In investment funds, new commitments amounted to EUR 98m. Both direct investments as investment funds were therefore above their annual target of EUR 150m and EUR 75m respectively. Going forward, Luxempart will aim to invest on average EUR 50m per ticket in order to have a meaningful impact on the NAV. At the same time, management also requires that all portfolio companies, regardless of the stake Luxempart has, grant Luxempart adequate governance rights. Luxempart wants to be an active partner in the companies it owns which is significantly different from the more passive approach we often see at other investment companies.

#### A year of streamlining

While investing significantly in existing companies like SNP and Technotrans, the Group also continued its streamlining strategy bringing the amount of portfolio lines from 43 to 33. This was of course supported by the takeover offers on Zooplus and Schaltbau. The streamlining will continue in 2022 as there are a few exit processes still ongoing. By the end of 2023, the company wants to have a portfolio of ~20 companies.

#### A year of ESG

Luxempart also increased its focus on ESG as the company reported a detailed Sustainability Report which the company intends to expand in the coming years. This trend is in line with what we have seen at other investment companies like Sofina for example. This offers the possibility of getting an attractive ESG rating and as a result being included in ESG funds or trackers.

EUR	12/18	12/19	12/20	12/21	-	-	-
<b>End FY Price</b>	50.50	53.00	49.00	74.50	-	-	-
<b>End FY NAV</b>	70.09	78.40	85.11	107.80	-	-	-
<b>End FY Discount</b>	-27.9%	-32.4%	-42.4%	-30.9%	-	-	-
<b>EPS</b>	3.44	10.31	7.80	24.81	-	-	-
<b>Cash EPS</b>	-	-	-	-	-	-	-
<b>Div.</b>	1.41	1.48	1.60	1.80	-	-	-
<b>Y/Y</b>	5.0%	5.2%	8.1%	12.5%	-	-	-
<b>Payout</b>	40.9%	14.4%	20.5%	-	-	-	-
<b>Yield</b>	2.9%	2.8%	3.3%	2.4%	-	-	-

## Strong portfolio performance 2021

Luxempart's NAV grew 27.4% over 2021 and 29.3% including the dividend distribution.

The private portfolio (excluding Foyer), performed very well with EBITDA increasing by 31% on average. Valuations remain very conservative at 10.3x EBITDA FY21 given the current elevated multiples in private equity. 26% of the NAV-increase over 2021 was related to capital gains vs. the last reported NAV which indeed underlines their conservative valuation approach. The fourteen largest companies presented in the annual report represent 54.6% of the consolidated NAV.

In Investment Funds, the company wants to invest between 75m and 100m in 2022 and to internationalize its exposure towards North America. This already started in 2021 as only 18% of the EUR 98m committed is to be deployed in Europe. The other 82% will be deployed in North America, Asia or on a global scale. This pillar has been a provider of excellent growth with a performance of 42.9% in 2021.

Treasury shares amounted to 574,735 or 2.8% of the outstanding shares. The AGM of 2021 also authorized a share buyback of up to 30% of its own shares for a price up to EUR 100 per share. This authorization expires at the AGM of April 25 2022 but it will be proposed to extend the authorization. We believe a SBB is not the right approach for Luxempart as it already suffers from a lack of liquidity. Instead, we hope that the 2.8% treasury shares and/or some of the existing shareholders might be interested to place their shares in the market. This would benefit the liquidity and hopefully the efficiency of the listing. Other possibilities of increasing liquidity would be an equity raise, a secondary listing on Euronext Brussels and a possible stock dividend.

## Foyer: the foundation of the portfolio

We estimate Foyer to represent ~35% of the GAV making it the biggest single line in the portfolio. Foyer is the insurance market leader in Luxembourg and also has exposure to wealth management in Belgium through CapitalAtWork.

Unfortunately, financial information about this stake remains limited. What is reported is that the net result grew to EUR 160m. We continue to believe that it would be beneficial for both Luxempart as investors if there would be more detailed information on the crown jewel of the portfolio. After all, the annual reports of Foyer are published on their own website. There we could read that for 2021, revenue grew 9.7%. Equity amounted to EUR 1.5bn, up 7.1% YoY. Operational result increased strongly to EUR 199.5m (+49.5%). The company also mentioned that its solvability ratio is comfortably above 200%.

Looking at valuation, Luxempart does not communicate at how much they value Foyer in the NAV. However, using the sectoral distribution of the portfolio, we can make an attempt. At the end of 2021, 44% of the direct investments were in financial services. This implies a valuation of EUR 623m. Luxempart holds 2 stakes in this sector: Foyer and iM Global. As Luxempart invested EUR 25m in iM Global combined with EUR 4m of additional investments, it implies a valuation of Foyer of EUR 594m. This is in line with our estimates. As Luxempart owns a 32% stake, this would bring valuation of the whole of Foyer to EUR 1.85bn. The 2021 P/B would therefore be ~1.27 which is in line with the sector.

## ESG: Becoming a key pillar of strategy

2021 was also a transformative year for ESG, which involved developing a sustainability framework, data collection, updating policies (including GDPR), and the creation of Sustainability Committee. Today, the Group deems it is not directly exposed to significant climate-related or other environmental risks. To preserve this, Luxempart established an exclusion list for its direct investments.

Going forward, the ESG strategy will be further developed in 2022. The action plan for this year consists of:

- The definition of a Sustainability policy
- Perform the first sustainability due diligences and prepare for the data collection
- Establish first reporting based on the approved sustainability framework
- Monitoring the constant evolution of the ESG legal and regulatory framework

We believe a significant differentiator between companies that score well or average on ESG is their data collection, quantified communication on key ESG metrics and the setting of ESG targets. This is an evolution also seen at Sofina for which 2021 was a year of data collection and communication of quantified metrics. We believe it will be beneficial for Luxempart if it decides to follow the same path.

## Our view: Important changes in progress with more to be expected in 2022

2021 was a good year for Luxempart but we do not think the party is over yet. We believe the management is committed to modernize Luxempart and make it future-proof. Establishing an ESG framework, streamlining the portfolio and internationalizing its portfolio are examples of that. We believe these measures are paying off. When we first started covering Luxempart, the stock was trading at a discount of ~40%. This has come down towards 30%. This also means there is still plenty of improvement possible as we believe a target discount of 15% is justified for Luxempart's portfolio.

In order to achieve a lower discount, we have suggested several options:

- Improving communication: Work in progress
- Continue dividend growth: 12.5% growth in 2021
- Increase liquidity

It is clear that Luxempart gets a check mark for the dividend growth. Also, on communication there have been several improvements including the sustainability report. One way to improve this is to communicate more clearly on Foyer. Many investors want to know more about the key portfolio line of Luxempart. After all, the annual report is published on the company's website.

A second catalyst would be the increase of liquidity. This could be achieved by either issuing new shares or existing shareholders lowering their stake. With a free float of <25%, we believe the company gets insufficient visibility. That combined with a very illiquid Luxembourg stock exchange, makes it for several investors (e.g. private banking) difficult to trade the stock due to liquidity constraints. Once again, we would like to stress that all these issues raised are technical factors and have nothing to do with the fundamentally strong portfolio. As we are confident that the management will try as much as possible to resolve these points over time, we believe a further rerating is still in the cards.

**Exhibit 1 NAV at 28/04/2022**

Participations	Spot value (€m)	Per share	% of GAV	12m Target
<b>Direct Investment (Listed)</b>	120.8	6.0	7%	126.9
<b>Direct Investments (Private)</b>	1,162.2	57.7	68%	1,301.6
of which Foyer (DPe)	587.0	29.2	34%	639.8
<b>Investment Funds</b>	437.5	21.7	25%	485.6
<b>Gross Asset Value (GAV)</b>	<b>1,720.5</b>	85.5	<b>100%</b>	<b>1,914.1</b>
Net cash	345.6	17.2		345.6
<b>Net Asset Value (NAV)</b>	<b>2,066.1</b>	102.7		<b>2,259.7</b>
per share	102.7			112.3
<b>Share price</b>	75.0			
	<b>Current</b>		<b>Hist. average</b>	<b>Target</b>
<b>Discount</b>	-27%		-30%	-15%
<b>Target range in EUR</b>			<b>79</b>	<b>96</b>

Source: Degroof Petercam estimates


**Share details Luxempart**

Share Price	75.00
NAV	102.66
Prem/(Disc)	-26.9%
Target	-15%
Dividend	1.80
Yield	2.4%
Target range	EUR 79-96

Last updated

28/04/2022


**NAV distribution**




**Historic discount average**

5Y average	-27.6%
10Y average	-31.7%


**5Y Share Price / NAV / Discount evolution**




**10Y Share Price / NAV / Discount evolution**



**Sector distribution direct investments**



**Geographical distribution direct investments**



## Commissioned Research

Degroof Petercam is commissioned by this company to publish research and is paid for this service.

## Disclosures applicable when indicated on the front page

1. Degroof Petercam acts as a liquidity provider for this company and is paid for these services.
2. Degroof Petercam has provided corporate finance services in the past 12 months for this company.

## General disclaimer

### About Degroof Petercam

This report has been prepared by Bank Degroof Petercam SA/NV ("Degroof Petercam").

Degroof Petercam is a financial institution authorised by and under the prudential supervision of, as a credit institution, the National Bank of Belgium and under the supervision of the Financial Services and Markets Authority. It has its registered office at 44, rue de l'Industrie, 1040 Brussels and is registered with the crossroads bank for enterprises under number 0403.212.172.

### No investment research

This report is considered as a marketing communication. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

### Not approved by the competent regulator

This report is not subject to any statutory prior approval requirement by a competent supervisory authority. As a result, this report has not been, and will not be submitted for approval to any competent supervisory authority.

### Content of the report

This report has been prepared by the sell-side research team of Degroof Petercam. All opinions, views, estimates and projections included herein reflect the personal views of the author on the subject company and related securities as of the date of this report. This report does not necessarily reflect the views of Degroof Petercam as institution and is subject to change without notice. The analyst(s) claim(s) furthermore not to have any meaningful financial interest in any of the aforementioned companies, not to be conflicted and not to have accepted any inducement from any person with a material interest in the subject company of the report at hand. The remuneration of the analysts is subject to the remuneration policy of Degroof Petercam and can be consulted [here](#).

The information and opinions contained in this report have been compiled or arrived at from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness.

### Validity of the report

Any information, opinion or estimate contained in the present report is, regardless of source, given in good faith and may only be valid as of the date on which this report is published and is subject to change. The value of any investment may also fluctuate as a result of market changes. Degroof Petercam is not obliged to inform the recipients of this report of any change to such opinions or estimates.

### Not for retail clients

This report is meant exclusively for professional clients or eligible counterparties (as defined in the Markets in Financial Instruments Directive 2014/65/EU) and is not intended for retail clients use.

### Review by the subject company of this report

Degroof Petercam reserves the right to submit a draft of the research report (excluding – where relevant - the target valuation range/fair value and the recommendation) for review to the subject company with the sole purpose of correcting any inadvertent material factual inaccuracies.

### Conflict of interest

It should be noted that Degroof Petercam and the subject company have entered into an agreement relating to the production of this report. Degroof Petercam has received a remuneration from the subject company for the drafting and dissemination of this report.. This remuneration is (i) a fixed fee which has been agreed between the subject company and Degroof Petercam prior to the drafting and publication of this report and (ii) under no circumstances positively or negatively influenced by the content of this report.

Due to the broad activities of the group to which Degroof Petercam belongs, it may occur that Degroof Petercam or any of its affiliates:

- holds positions or effect transactions in the securities of the company mentioned herein or any member of its group;
- performs or seeks to perform investment banking services for such companies (such as corporate finance advice services);
- acts as a market maker or a liquidity provider for the securities of the company mentioned herein;
- performs any other services it is legally entitled to provide;
- hold a mandate in the subject company;
- hold a significant stake in the subject company.

In this regard, Degroof Petercam is required to have arrangements in place to identify, prevent and manage conflicts of interest between itself and clients and between different clients. Degroof Petercam operates in accordance with a conflicts of interest policy under which Degroof Petercam has identified those situations in which there may be a conflict of interest and, in each case, the steps taken to manage that conflict. Degroof Petercam has taken reasonable care to ensure that objectivity of this research report and the independence of the author are ensured and it has put in place several arrangements (such as internal policies and procedures) in order to manage potential conflicts of interests. Degroof Petercam has for example implemented

a remuneration policy, a personal account dealing procedure and several organizational measures such as Chinese Walls which are designated to prevent against the wrongful disclosure and use of confidential and sensitive information. Where the arrangements under our conflicts of interest policy are not sufficient to manage a particular conflict, Degroof Petercam will inform the relevant client of the nature of the conflict so that the client can make a well-informed decision. Next to the aforementioned arrangements, Degroof Petercam has also implemented the internal arrangements required by article 37(1) of the Commission Delegated Regulation 2017/565.

**No offer**

This report does not constitute and should not be construed as, an offer or solicitation for the sale, purchase or subscription of any financial instrument. Any offer or entry into any transaction requires Degroof Petercam's subsequent formal agreement which may be subject to internal approvals and execution of binding transaction documents.

**No investment advice**

The information contained in this report should not be regarded as personalized and should not be considered as a recommendation of investment advice. Recipients should not construe the contents of this report as legal, tax, accounting or investment advice or personal recommendation. Accordingly Degroof Petercam is under no obligation to, and shall not, determine the suitability for the recipient of any potential transaction described herein. Recipients should seek advice to their advisors in order to determine the merits, terms, conditions and risks of any potential transaction that may be described herein.

**Forward looking statements**

This report may contain forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the actual results, condition, performance, prospects, growth or opportunities to differ materially from those expressed in, or suggested by, these forward-looking statements. Forward-looking statements are not guarantees of future performance and there is no guarantee that any of the estimates or projections will be achieved. Actual results may vary from the projections and such variation may be material.

**Past & simulated past performance**

Any past or simulated past performance including back-testing, modelling or scenario analysis contained herein is no indication as to future performance. No representation is made as to the accuracy of the assumptions made within, or completeness of, any modelling, scenario analysis or back-testing.

**Valuation method**

Our target valuation is generally based on a combination of valuation methods including DCF, SOTP, peer group comparison, historical ratio analysis and others. The outcome of these valuation methods is sensitive to both external factors (e.g. interest rates and market valuations) and assumptions we make (e.g. on sales growth, profitability, or valuation discounts). Be aware that even small changes in these elements can lead to large changes in target valuation. More information on the valuation method used for this company can be found in the reports published on <https://www.degroofpetercam.com/en-be/commissioned-research>

**No liability**

Degroof Petercam accepts no liability whatsoever for any direct or consequential loss or damage arising from any use of this report or its contents. This report does not purport to give an exhaustive description of the financial instrument and of the issuer of the financial instrument it relates to. Although all reasonable care has been taken to ensure that the information in this report is accurate, neither Degroof Petercam, nor any of its affiliated companies, directors, advisors or employees can be held liable for any incorrect, incomplete or missing information, or for any direct or indirect damage, losses, costs, claims, liabilities or other expenses which would result from the use of, or reliance on, this report, except in case of willful misconduct or gross negligence. The information contained in this report has not been independently verified by any independent third party.

**Distribution restriction**

The present report is exclusively intended to professional clients and eligible counterparties, to the exclusion of retail clients. It may not be copied, reproduced, marketed or distributed in whole or in part for any purpose whatsoever without the prior written consent of Degroof Petercam.

The present report may not be taken or transmitted or distributed, directly or indirectly, outside of the EEA (but for the United Kingdom).

## Report completion and updates

This report was first disseminated by Degroof Petercam on 28 April 2022 08:07 CET

Valuations are continuously reviewed by the analyst and will be updated and/or refreshed regularly. The rationale behind a change in target valuation will be explained in such a refresher/update.

An overview of the research published on this company can be found on our website: <https://www.degroofpetercam.com/en-be/commissioned-research> This website will also give you access to all of the commissioned research reports that have been disseminated during the preceding 12-month period.

This report has not been reviewed by the company prior to publication.

The report has been reviewed by David Seynnaeve, equity analyst.



# Degroof Petercam Global Markets

www.degroofpetercam.com

Nijverheidsstraat / Rue de l'Industrie 44 – 1040 Brussels

De Entrée 238 A 7<sup>th</sup> floor – 1101 EE Amsterdam

**Benoît Mortelmans** +32 2 662 82 93

## Equity Research / Analysts

<b>Fernand de Boer</b>	Retail/Food & Beverages	+31 20 573 5417
<b>Kris Kippers</b>	Consumer Goods/Holdings	+32 2 287 9259
Frank Claassen	Industrials	+31 20 573 5409
Christophe Dombu Youta, PhD	Biotech/Healthcare	+32 2 287 9051
Vivien Maquet	Telecom/Utilities/Real Estate	+32 2 662 8446
Inna Maslova	Real Estate	+32 2 662 8644
Laura Roba	ESG/Medtech	+32 2 287 9276
Michael Roeg	Technology	+31 20 573 5422
David Seynnaeve, PhD	Biotech/Healthcare	+32 2 287 9771
Joren Van Aken	Holdings/Misc.	+32 2 662 8883
Luuk van Beek	Energy/Engineering/Construction	+31 20 573 5471
Herman van der Loos, CFA	Real Estate	+32 2 662 8304
Christel De Clerck	Support & Editing	+32 2 662 8302

## Corporate Brokerage & Syndication

<b>Gert Potvlieghe</b>		+32 2 662 8289
Raymond de Wolff		+31 20 573 5414
Tineke Hosselaer	Corporate access	+32 2 662 8290
Charlotte Mertens	Corporate access	+31 20 573 5416

## Sales

<b>Anthony della Faille</b>	+32 2 662 8724
<b>Laurent Pierret</b>	+32 2 662 8654

## Equity Sales

<b>Simon Vlamincx</b>	+32 2 662 8291
<b>Damien Fontaine</b>	+32 2 662 8287
Assia Adanouj	+32 2 662 8768
Piethain Leune	+31 20 573 5436
Jeroen Van Genuchten	+31 20 573 5428
Beatrice Leysens - Assistant	+32 2 662 8262

## Sales Trading

<b>Veronique De Schoemaeker</b>	+32 2 662 8280
Fabrice Faccenda	+32 2 662 8986
Frédéric Lebrun	+32 2 287 9190

## Fixed Income Sales

<b>An-Sofie Meirsschaut</b>	+32 2 662 8665
Sandra Timmermans	+32 2 662 8852
Olivier Gigounon	+32 2 287 9184

## Derivatives

<b>Karim Marrakchi</b>	+32 2 662 8940
Eric Debeaud	+32 2 287 9827
Thierry De Wispelaere	+32 2 662 8674